Disease progression in C9orf72 mutation carriers

被引:32
|
作者
Floeter, Mary K. [1 ]
Traynor, Bryan J. [2 ]
Farren, Jennifer [1 ]
Braun, Laura E. [1 ]
Tierney, Michael [1 ]
Wiggs, Edythe A. [1 ]
Wu, Tianxia [1 ]
机构
[1] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA
[2] NIA, NIH, Bethesda, MD 20892 USA
关键词
AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL DEMENTIA; BEHAVIORAL VARIANT; REPEAT EXPANSION; HEXANUCLEOTIDE REPEAT; CLINICAL-TRIALS; RATING-SCALE; ALS; COGNITION; DECLINE;
D O I
10.1212/WNL.0000000000004115
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To assess changes in 3 clinical measures, the Revised ALS Functional Rating Scale (ALSFRS-R), letter fluency, and Frontal Behavioral Inventory (FBI), over time in C9orf72 mutation carriers (C9+) with varied clinical phenotypes. Methods: Thirty-four unrelated participants with mutations in C9orf72 were enrolled in a prospective natural history study. Participants were classified as asymptomatic, amyotrophic lateral sclerosis (ALS), ALS-familial frontotemporal dementia (FTD), or behavioral-variant FTD by clinical diagnostic criteria. Diagnostic cognitive and motor tests were repeated at 6 and 18 months. The ALSFRS-R, letter fluency, and FBI were administered at baseline and follow-up visits at 6, 12, and 18 months. Results: The clinical diagnosis of most patients did not change over the follow-up. ALSFRS-R scores correlated with measures of motor function. Letter fluency correlated with FBI and cognitive tests. ALSFRS-R, letter fluency, and FBI differed among the C9+ diagnostic subgroups at enrollment and worsened over follow-up in symptomatic patients, with different slopes among the subgroups. Most patients survived to the 6-month time point after enrollment. Survival of C9+ patients with ALS and C9+ patients with ALS-FTD declined over the 12- and 18-month follow-up. Conclusions: The pattern of scores of the ALSFRS-R, letter fluency, and FBI distinguished between ALS, ALS-FTD, and FTD presentations of C9orf72 mutation carriers and asymptomatic carriers. Longitudinal changes in these measures occurred with disease progression in a manner consistent with presenting phenotype.
引用
收藏
页码:234 / 241
页数:8
相关论文
共 50 条
  • [31] The Phenotype of the C9ORF72 Expansion Carriers According to Revised Criteria for bvFTD
    Solje, Eino
    Aaltokallio, Heidi
    Koivumaa-Honkanen, Heli
    Suhonen, Noora M.
    Moilanen, Virpi
    Kiviharju, Anna
    Traynor, Bryan
    Tienari, Pentti J.
    Hartikainen, Paivi
    Remes, Anne M.
    PLOS ONE, 2015, 10 (07):
  • [32] Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion
    De Vocht, Joke
    Blommaert, Jeroen
    Devrome, Martijn
    Radwan, Ahmed
    Van Weehaeghe, Donatienne
    De Schaepdryver, Maxim
    Ceccarini, Jenny
    Rezaei, Ahmadreza
    Schramm, Georg
    van Aalst, June
    Chio, Adriano
    Pagani, Marco
    Stam, Daphne
    Van Esch, Hilde
    Lamaire, Nikita
    Verhaegen, Marianne
    Mertens, Nathalie
    Poesen, Koen
    van den Berg, Leonard H.
    van Es, Michael A.
    Vandenberghe, Rik
    Vandenbulcke, Mathieu
    Van den Stock, Jan
    Koole, Michel
    Dupont, Patrick
    Van Laere, Koen
    Van Damme, Philip
    JAMA NEUROLOGY, 2020, 77 (08) : 1008 - 1017
  • [33] C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers
    Patrizia Rizzu
    Cornelis Blauwendraat
    Sasja Heetveld
    Emily M. Lynes
    Melissa Castillo-Lizardo
    Ashutosh Dhingra
    Elwira Pyz
    Markus Hobert
    Matthis Synofzik
    Javier Simón-Sánchez
    Margherita Francescatto
    Peter Heutink
    Acta Neuropathologica Communications, 4
  • [34] Presymptomatic spinal cord pathology in c9orf72 mutation carriers: A longitudinal neuroimaging study
    Querin, Giorgia
    Bede, Peter
    El Mendili, Mohamed Mounir
    Li, Menghan
    Pelegrini-Issac, Melanie
    Rinaldi, Daisy
    Catala, Martin
    Saracino, Dario
    Salachas, Francois
    Camuzat, Agnes
    Marchand-Pauvert, Veronique
    Cohen-Adad, Julien
    Colliot, Olivier
    Le Ber, Isabelle
    Pradat, Pierre-Francois
    ANNALS OF NEUROLOGY, 2019, 86 (02) : 158 - 167
  • [35] C9ORF72 expansion in a family with bipolar disorder
    Meisler, Miriam H.
    Grant, Adrienne E.
    Jones, Julie M.
    Lenk, Guy M.
    He, Fang
    Todd, Peter K.
    Kamali, Masoud
    Albin, Roger L.
    Lieberman, Andrew P.
    Langenecker, Scott A.
    McInnis, Melvin G.
    BIPOLAR DISORDERS, 2013, 15 (03) : 326 - 332
  • [36] CORTICAL HYPEREXCITABILITY IN PATIENTS WITH C9ORF72 MUTATIONS: RELATIONSHIP TO PHENOTYPE
    Schanz, Olivia
    Bageac, Devin
    Braun, Laura
    Traynor, Bryan J.
    Lehky, Tanya J.
    Floeter, Mary Kay
    MUSCLE & NERVE, 2016, 54 (02) : 264 - 269
  • [37] C9orf72 nucleotide repeat structures initiate molecular cascades of disease
    Haeusler, Aaron R.
    Donnelly, Christopher J.
    Periz, Goran
    Simko, Eric A. J.
    Shaw, Patrick G.
    Kim, Min-Sik
    Maragakis, Nicholas J.
    Troncoso, Juan C.
    Pandey, Akhilesh
    Sattler, Rita
    Rothstein, Jeffrey D.
    Wang, Jiou
    NATURE, 2014, 507 (7491) : 195 - +
  • [38] No common founder for C9orf72 expansion mutation in Sweden
    Chiang, Huei-Hsin
    Forsell, Charlotte
    Lindstrom, Anna-Karin
    Lilius, Lena
    Thonberg, Hakan
    Nennesmo, Inger
    Graff, Caroline
    JOURNAL OF HUMAN GENETICS, 2017, 62 (02) : 321 - 324
  • [39] Mutation in C9orf72 changes the boundaries of ALS and FTD
    Andersen, Peter M.
    LANCET NEUROLOGY, 2012, 11 (03) : 205 - 207
  • [40] Factors predicting disease progression in C9ORF72 ALS patients
    Jessica Mandrioli
    Elisabetta Zucchi
    Ilaria Martinelli
    Laura Van der Most
    Giulia Gianferrari
    Cristina Moglia
    Umberto Manera
    Luca Solero
    Rosario Vasta
    Antonio Canosa
    Maurizio Grassano
    Maura Brunetti
    Letizia Mazzini
    Fabiola De Marchi
    Cecilia Simonini
    Nicola Fini
    Rossella Tupler
    Marco Vinceti
    Adriano Chiò
    Andrea Calvo
    Journal of Neurology, 2023, 270 : 877 - 890